CE19 - Technologies pour la santé

New gallium-68 complexes for PET imaging of aggrecans – ImAgGa

Submission summary

The ImAgGa project consists in developing a new gallium-68 radiotracer highly specific to articular cartilage proteoglycan aggrecan. This new complex will allow early diagnosis and quantification of osteoarthritis as well as its longitudinal follow-up by PET imaging. Such a tool is essential for the evaluation of Disease-Modifying OsteoArthritis Drugs (DMOADs) that are under development. The synthesis of several kind of bifunctionalized ligand structures will be undertaken. The best radiotracer will be selected according to criteria such as effective radiolabeling, stability of the complex in plasma and/or serum, binding affinity of the complexes toward aggrecans (determination of Kd by MicroScaleThermophoresis), biodistribution in an healthy animal model (i.e. high cartilage-specific binding). The selected compound will then be evaluated in preclinical studies on an osteoarthritic animal model treated or not with a promising DMOAD. Lastly, a dosimetric study and development of a radiolabeling kit will be carried out.

Project coordination

Vincent GAUMET (Imagerie moléculaire et stratégies theranostiques)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CRSA Centre de Recherche Saint-Antoine
LPC LABORATOIRE DE PHYSIQUE DE CLERMONT
IMOST Imagerie moléculaire et stratégies theranostiques

Help of the ANR 405,211 euros
Beginning and duration of the scientific project: December 2022 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter